Bone metastases in advanced prostate cancer. Management

6/20/22, 12:19 AM 17128
Skeletal events during systemic treatment for metastatic prostate cancer
Drugs
Definition
of skeletal
events
Method
of
assessing
skeletal
events
Median
time to
first SRE
(months)
Hazard
ratio
(95%
CI)
p
value
Saad, et al
Zoledronic acid
Pathologic
Periodic
16.0 versus
0.68 <0.01
(2002,
(n = 214) versus
fractures;
radiologic
10.5
2004)
placebo (n =
EBRT to bone,
review:
208)
surgery to
skeletal
bone; SCC;
surveys
change in
every 3
neoplastic
months
therapy for
bone pain
Fizazi, et al
Denosumab (n =
Pathologic
Periodic
20.7 versus
0.82 <0.001
(2011)
950) versus
fracture; EBRT
radiologic
17.1
zoledronic acid
to bone; SCC;
review:
(n = 951)
surgery to
skeletal
bone
surveys
every 12
weeks
Scher, et al
Enzalutamide (n
Pathologic
No periodic
16.7 versus
0.69 <0.01
(2012)
= 800) versus
fracture, EBRT
radiologic
13.3
placebo (n =
to bone; SCC,
review
399)
surgery to
bone; change
in
antineoplastic
therapy for
bone pain
Logothetis,
Abiraterone plus
Pathologic
No periodic
25.0 versus
0.62 <0.001
et al (2012)
prednisone (n =
fracture; EBRT
radiologic
20.3
797) versus
to bone, SCC,
review
placebo plus
or surgery to
prednisone (n =
bone
398)
Parker, et
Radium-
Pathologic
No periodic
15.6 versus
0.66 <0.001
al (2013)
223 plus BSC (n
fracture; EBRT
radiologic
9.8
= 614) versus
to bone; SCC;
review
https://www.uptodate.com/contents/17128/print 24/27